|Articles|November 19, 2015

Michael J. Mauro on Questions From Patients With CML

Michael J. Mauro, provides an overview of some of the questions he hears from patients with chronic myeloid leukemia (CML).

Michael J. Mauro, leader, Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, provides an overview of some of the questions he hears from patients with chronic myeloid leukemia (CML).

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!

Related Content

Real-Time Text Tool Tracks Quality of Life in Myeloma Care

ByDr. James Berenson

December 7th 2025

Fixed Duration Venclexta Combos Delay Progression in CLL Similarly to Imbruvica

ByGina Mauro

December 6th 2025

Pediatric and AYA B-ALL Treatment Effective Without Total Body Irradiation

ByAriana Pelosci

December 6th 2025

Families of Children With ALL Face Catastrophic Financial Toxicity

ByAlex Biese

December 6th 2025

Dr. Thomas Marron explains how therapeutic vaccines differ from preventative vaccines in lung cancer care.

How Therapeutic Vaccines May Transform Lung Cancer Care

ByDr. Thomas Marron

December 5th 2025

Michael J. Mauro on Questions From Patients With CML

Newsletter

Related Content

Real-Time Text Tool Tracks Quality of Life in Myeloma Care

Fixed Duration Venclexta Combos Delay Progression in CLL Similarly to Imbruvica

Pediatric and AYA B-ALL Treatment Effective Without Total Body Irradiation

Families of Children With ALL Face Catastrophic Financial Toxicity

How Therapeutic Vaccines May Transform Lung Cancer Care

Trending on CURE

Every FDA Oncology Approval From November 2025

Reflecting on My Sister’s Final Days After Years of Unexpected Rebounds

Chemo Side Effects for Breast Cancer Led to Weeks in the Hospital

First Annual Blood Cancer Heroes Honors Leaders, Advocates and Survivors

Fixed Duration Venclexta Combos Delay Progression in CLL Similarly to Imbruvica